CTC immune escape mediated by PD-L1

Medical Hypotheses

Volumn 93, Issue , 2016, Pages 138-139

  Wang, Xuefei ^a,b   Sun, Qiang ^a,b   Liu, Qiaofei ^a,b   Wang, Changjun ^a,b   Yao, Ru ^a,b   Wang, Yimin ^a,b  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; PROGRAMMED DEATH 1 RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GRADING; CANCER PROGNOSIS; CELL PROTECTION; CELL SURFACE; CIRCULATING TUMOR CELL; HUMAN; METASTASIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR ESCAPE; ANIMAL; BONE MARROW CELL; BREAST TUMOR; CELL MEMBRANE; CLUSTER ANALYSIS; CYTOLOGY; DISEASE MODEL; FEMALE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; MOUSE; PATHOLOGY; PROGNOSIS; THEORETICAL MODEL; TUMOR EMBOLISM;

ANIMALS; ANTIGENS, CD274; BONE MARROW CELLS; BREAST NEOPLASMS; CELL MEMBRANE; CLUSTER ANALYSIS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MICE; MODELS, THEORETICAL; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES, REGULATORY;

EID: 84979622747     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2016.05.022     Document Type: Article

References (19)

1. [1] Chen, W., Zheng, R., Baade, P.D., Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 10.3322/caac.21338 [Epub ahead of print].
2. [2] Chang, M.C., Chang, Y.T., Chen, J.Y., Clinical Significance of Circulating Tumor Microemboli as a Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma. Clin Chem., 2016 pii: clinchem.2015.248260. [Epub ahead of print].
3. [3] Phillips, K.G., Lee, A.M., Tormoen, G.W., The thrombotic potential of circulating tumor microemboli: computational modeling of circulating tumor cell-induced coagulation. Am J Physiol Cell Physiol 308:3 (2015), C229–C236, 10.1152/ajpcell.00315.2014 Epub 2014 Nov 19.
4. [4] Sarioglu, A.F., Aceto, N., Kojic, N., A microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nat Methods 12:7 (2015), 685–691, 10.1038/nmeth.3404 Epub 2015 May 18.
5. [5] Strauss, L., Bergmann, C., Szczepanski, M., Gooding, W., Johnson, J.T., Whiteside, T.L., A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 13:15 Pt 1 (2007), 4345–4354.
6. [6] Whiteside, T.L., Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16:1 (2006), 3–15, 10.1016/j.semcancer.2005.07.008.
7. [7] Francisco, L.M., Salinas, V.H., Brown, K.E., Vanguri, V.K., Freeman, G.J., Kuchroo, V.K., et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206 (2009), 3015–3029 [PMC free article] [PubMed].
8. [8] Zhou, Q., Munger, M.E., Highfill, S.L., Tolar, J., Weigel, B.J., Riddle, M., et al. Program death-1 (PD-1) signaling and regulatory T cells (Tregs) collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes (CTLs) in advanced acute myeloid leukemia (AML). Blood 116 (2010), 2484–2493 [PMC free article] [PubMed].
9. [9] Fife, B.T., Pauken, K.E., Eagar, T.N., Obu, T., Wu, J., Tang, Q., et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 10:11 (2009), 1185–1192.
10. [10] Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., Saito, T., Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med 209:6 (2012), 1201–1217.
11. [11] Wang, X.F., Sun, Q., Mao, F., CTCs hemodialysis: can it be a new therapy for breast cancer?. Med Hypotheses 80:1 (2013), 99–101, 10.1016/j.mehy.2012.06.025 Epub 2012 Nov 24.
12. [12] Kurt, A., Schalper1, vamsidhar velcheti3, Daniel Carvajal1, In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res 20:10 (2014), 2773–2782 AACR.
13. [13] Tao Qin, Yin-duo Zeng, Ge Qin, High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer, Oncotarget, Vol. 6, No.32.
14. [14] Mauricio Z. Baptista, Luis Otavio Sarian, Sophie F.M. Derchain, Prognostic significance of PD-L1 and PD-L2 in breast cancer, Human Pathol (2015) xx, xxx–xxx http://dx.doi.org/10.1016/j.humpath.2015.09.006.
15. [15] In Hae Park, Sun-Young Kong, Jae Yoon Ro, Prognostic Implications of tumor-infiltrating lymphocytes in association with programmed death ligand 1 expression in early-stage breast cancer, Clin Breast Cancer, 16 (1), 51–8 http://dx.doi.org/10.1016/j.clbc.2015.07.006.
16. [16] Ashley Cimino-Mathews, Elizabeth Thompson, Janis M. Taube, PD-L1 (B7–H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas, Human Pathology (2015) xx, xxx–xxx, http://dx.doi.org/10.1016/j.humpath.2015.09.003.
17. [17] Muenst S, Schaerli AR, Gao F, Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer, Breast Cancer Res Treat, http://dx.doi.org/10.1007/s10549-014-2988-5.
18. [18] Renaud Sabatier, Pascal Finetti, Emilie Mamessier, Prognostic and predictive value of PDL1 expression in breast cancer, Oncotarget, Vol. 6, No.7.
19. [19] Mazel, M., Jacot, W., Pantel, K., Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol 9:9 (2015), 1773–1782, 10.1016/j.molonc.2015.05.009 Epub 2015 Jun 9.